We want you to take advantage of everything Clinical Advisor has to offer. To view unlimited content, log in or register for ...

Tardive dyskinesia (TD) is an involuntary movement condition, meaning you can't control your movements. "Tardive" means late, and "dyskinesia" means uncontrolled movements. It's often a side ...

Tardive Dyskinesia TD as a neurological disorder resulting in involuntary repetitive movement disorder as a disease of brain Neurology due to dopamine problems. What have studies said the role ...

The global Deuterated Drugs Market is witnessing remarkable momentum as it charts a growth trajectory from a valuation of US$ 334.0 million in 2023 to an anticipated US$ 871.8 million by 2032, ...

Incidence rates of tardive movement syndromes (tardive dyskinesia and tardive dystonia; TDD) were examined. A priori hypothesized associations between incident TDD and other dopamine proxies (e.g ...

Tardive dyskinesia is a medication-induced movement disorder. It's typically caused by certain classes of medicines that block dopamine receptors in the brain. The typical offenders are a class of ...

HealthDay News — Disruptions in amino acid and lipid metabolism may be biomarkers of tardive dyskinesia (TD), according to a study published online February 21 in Schizophrenia Bulletin.

However, the FDA recently placed a black-box warning on metoclopramide because of the risk of related side effects, including tardive dyskinesia, the incidence of which has been cited to be as ...

THURSDAY, March 20, 2025 (HealthDay News) -- Disruptions in amino acid and lipid metabolism may be biomarkers of tardive dyskinesia (TD), according to a study published online Feb. 21 in Schizophrenia ...

"These findings further establish INGREZZA as a highly effective long-term treatment option for individuals living with tardive dyskinesia ... of tardive dyskinesia (TD) symptoms using the ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...